

ADDITIONAL FILE 1

Table 1. Demographic parameters of the whole cohort at baseline

Demographic parameters	Value (n=81 patients)
Age, years median (range)	12.6 (1.7-18.3)
Disease duration, years median (range)	
Global	3.7 (0.1-15.1)
Naïve patients (n=16)	0.8 (0.1-7.8)
Established patients (n=65)	3.9 (0.3-15.1)
Female sex n (%)	53 (65.4)
Categories of JIA n (%)	
Systemic	11 (13.6)
Oligoarthritis	46 (56.8)
<i>Persistent</i>	37 (80.4)
<i>Extended</i>	9 (19.6)
PA-RF+	3 (3.7)
PA-RF-	7 (8.6)
Psoriatic arthritis	1 (1.2)
ERA	11 (13.6)
Undifferentiated	2 (2.5)
Treatment history n (%)	
Intraarticular corticosteroids / <i>ongoing</i>	40 (49.4) / 8 (9.9)
Oral corticosteroids / <i>ongoing</i>	38 (46.9) / 7 (8.6)
MTX / <i>ongoing</i>	72 (88.9) / 61 (75.3)
Other csDMARD / <i>ongoing</i>	11 (13.6) / 8 (9.9)
Any biologics / <i>ongoing</i>	35 (43.2) / 22 (27.2)
Anti-TNF / <i>ongoing</i>	29 (35.8) / 15 (18.5)
Tocilizumab / <i>ongoing</i>	8 (9.9) / 3 (3.7)
Anti-IL1 / <i>ongoing</i>	3 (3.7) / 3 (3.7)
Abatacept / <i>ongoing</i>	2 (2.5) / 1 (1.2)

JIA, juvenile idiopathic arthritis; PA, polyarthritis; RF, rheumatoid factor; ERA, enthesitis-related arthritis; MTX, methotrexate; csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; TNF, tumor necrosis factor; IL1, interleukin-1.